Apply to trial NCT05868837

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 3Drug trial

Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)

The primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening